- Conditions
- Healthy
- Interventions
- ALS-008176, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- BMS-986278, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
- Interventions
- Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
- Drug
- Lead sponsor
- Food and Drug Administration (FDA)
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- QTc Interval, Pharmacokinetics
- Interventions
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Drug
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteer
- Interventions
- Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas